- Home
- / Imara
Imara
Stock Price
$21
2023-02-27
Market Capitalization
$166.1 M
2023-02-27
Imara Summary
Company Summary
- Overview
- Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. The Company offers IMR-687, an oral, and selective phosphodiesterase 9 (PDE9) inhibitor to treat patients with sickle cell disease by both reducing red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology of sickle cell disease.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Boston, MA, US | view all locations
- Website
- http://imaratx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Stephen M. Migausky, Senior Vice President, Legal and General Counsel
David M. Mott, Director
David Bonita, Director
Imara Financials
Summary Financials
- Net income (FY, 2024)
- ($89.0M)
- Cash (FY, 2024)
- $124.1M
- EBIT (FY, 2024)
- ($104.6M)